HeartSciences targets FDA De Novo resubmission around fiscal year end; cash $3.1M

HeartSciences Inc.

Patient enrollment for MyoVista pivotal study near completion; resubmission target around April 2023 fiscal year-end.
Cash and cash equivalents $3.1M as of Oct 31, 2022; sufficient through FDA resubmission.
No meaningful revenue in Q2 fiscal 2023 as development-stage company.
Entered multi-year collaboration with Rutgers University for AI algorithm development.
AMA issued new Category III CPT codes covering AI assistive ECG risk assessments for cardiac dysfunction.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.85

HeartSciences Inc. reported financial results for the fiscal 2023 second quarter ended October 31, 2022.

Period: the fiscal 2023 second quarter ended October 31, 2022
Result: reported results

Exact text from the filing

On December 16, 2022, Heart Test Laboratories, Inc. (the "Company") issued a press release providing information regarding the Company's financial and operating results for the quarter ended October 31, 2022, and other business updates.

View on SEC.gov

Browse all earnings releases →

HeartSciences Inc. filing history →

Source: SEC EDGAR

accession 0000950170-22-026929

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.